Scalability and reproducibility of the AAV9 capture step using KRM™ Chromatography System Application Note
Advancing the disease indications of cell and gene therapies (GT) beyond rare diseases, as well as developing more complex, yet fragile viral vectors, requires not only expanding existing manufacturing facilities, but also developing new approaches.